Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.
about
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectiveThe relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell linesOligopeptide inhibition of class I ribonucleotide reductases.Analysis of deoxyribonucleotide pools in human cancer cell lines using a liquid chromatography coupled with tandem mass spectrometry techniquePemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma.Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression.Profiling ribonucleotide and deoxyribonucleotide pools perturbed by gemcitabine in human non-small cell lung cancer cells.Sensitive liquid chromatography mass spectrometry (LC-MS) assay reveals novel insights on DNA methylation and incorporation of gemcitabine, its metabolite difluorodeoxyuridine, deoxyuridine, and RX-3117 into DNA.Fully validated assay for the quantification of endogenous nucleoside mono- and triphosphates using online extraction coupled with liquid chromatography-tandem mass spectrometry.Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360).EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer.Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.Effects of antibiotic antitumor drugs on nucleotide levels in cultured tumor cells: an exploratory method to distinguish the mechanisms of antitumor drug action based on targeted metabolomicsIncreased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines.Exploring the Potent Inhibition of CTP Synthase by Gemcitabine-5'-Triphosphate.Ground state, intermediate, and multivalent nucleotide analogue inhibitors of cytidine 5'-triphosphate synthase.Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer.Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group.
P2860
Q26752368-DA37A56A-6CF4-46DA-812E-9D4A28BC518BQ33245149-3B88F953-7B2B-4A3F-B77A-10E725A70311Q34199980-54FFB142-DFE0-4F78-9860-F8A1704535FFQ35113244-C581ADFD-589E-4BB5-9CAD-3E64EDCB5098Q35135650-6DF0F8E1-436A-43BD-8E5D-05681BBC887BQ36924856-02236E40-DE88-475D-A849-24F1E58D660EQ37413849-1748EDCD-4377-4765-80D2-11BF3F9EA7E6Q38728083-F86A300C-B6DB-4C47-9312-6A23E4624485Q39014985-D5F86297-F34B-4DDD-AB6C-8598F174F5F6Q39094261-E5412B76-20F4-4F35-8D51-2143322A5FA5Q39151780-C0392701-AE8B-4B37-A601-116F8A313660Q40460534-B84304D6-E7D3-4FAD-B0FB-921FED5F40D2Q42005150-FA7958B9-99AE-41D3-A763-1FF005B49931Q42142458-E8CD8005-3F6A-44CE-B9BA-BD2FC54FE636Q43202485-8871235F-9A5F-49A2-9A27-4693BD884084Q46215323-81E24DB6-77E4-49A1-9EBB-37BC8CB219B3Q46261296-91BD745A-C034-424B-ACA2-8519E205B38DQ46980070-3AB43116-7962-4B13-BDE2-B6136FA44F49Q49504547-57938D87-24F7-48CB-BF7E-0612F4D7137D
P2860
Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Differential effects of gemcit ...... mour and leukaemia cell lines.
@en
type
label
Differential effects of gemcit ...... mour and leukaemia cell lines.
@en
prefLabel
Differential effects of gemcit ...... mour and leukaemia cell lines.
@en
P2093
P1476
Differential effects of gemcit ...... umour and leukaemia cell lines
@en
P2093
A M Bergman
C J van Moorsel
G J Peters
H M Pinedo
V W Ruiz van Haperen
P356
10.1016/S0304-4165(99)00209-3
P577
2000-03-01T00:00:00Z